Recurrent candidal intertrigo: challenges and solutions
- PMID: 29713190
- PMCID: PMC5909782
- DOI: 10.2147/CCID.S127841
Recurrent candidal intertrigo: challenges and solutions
Abstract
Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or periorificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required.
Keywords: Candida; candidal predisposals; candidiasis; candidosis; intertrigo; recurrent candidal intertrigo.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family.J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2 Suppl 3):89-93. J Biol Regul Homeost Agents. 2016. PMID: 27498664 Clinical Trial.
-
Resistant "candidal intertrigo": could inverse psoriasis be the true culprit?J Am Board Fam Med. 2013 Mar-Apr;26(2):211-4. doi: 10.3122/jabfm.2013.02.120210. J Am Board Fam Med. 2013. PMID: 23471936
-
Intertrigo and secondary skin infections.Am Fam Physician. 2014 Apr 1;89(7):569-73. Am Fam Physician. 2014. PMID: 24695603
-
Oral candidosis--clinical challenges of a biofilm disease.Crit Rev Microbiol. 2011 Nov;37(4):328-36. doi: 10.3109/1040841X.2011.585606. Epub 2011 Jul 21. Crit Rev Microbiol. 2011. PMID: 21777047 Review.
-
[Guidelines for diagnosis and treatment of mucocutaneous candidiasis].Nihon Ishinkin Gakkai Zasshi. 2009;50(4):207-12. doi: 10.3314/jjmm.50.207. Nihon Ishinkin Gakkai Zasshi. 2009. PMID: 19942790 Review. Japanese.
Cited by
-
Candida albicans-The Virulence Factors and Clinical Manifestations of Infection.J Fungi (Basel). 2021 Jan 22;7(2):79. doi: 10.3390/jof7020079. J Fungi (Basel). 2021. PMID: 33499276 Free PMC article. Review.
-
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks.J Clin Med. 2020 Nov 8;9(11):3594. doi: 10.3390/jcm9113594. J Clin Med. 2020. PMID: 33171581 Free PMC article. Review.
-
Unveiling the mechanism of essential oil action against skin pathogens: from ancient wisdom to modern science.Arch Microbiol. 2024 Jul 10;206(8):347. doi: 10.1007/s00203-024-03986-6. Arch Microbiol. 2024. PMID: 38985339 Review.
-
Preparation and Optimization of Itraconazole Transferosomes-Loaded HPMC Hydrogel for Enhancing Its Antifungal Activity: 2^3 Full Factorial Design.Polymers (Basel). 2023 Feb 16;15(4):995. doi: 10.3390/polym15040995. Polymers (Basel). 2023. PMID: 36850278 Free PMC article.
-
Therapeutic pearl: A simple cost-effective treatment for chronic digital intertrigo of toes.J Cutan Aesthet Surg. 2024 Jul-Sep;17(3):256-258. doi: 10.4103/JCAS.JCAS_127_21. Epub 2022 Dec 2. J Cutan Aesthet Surg. 2024. PMID: 39483661 Free PMC article.
References
-
- Vakharia P. Intertrigo. 2017. [Accessed August 1, 2017]. http://emedicine.medscape.com/article/1087691.
-
- Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician. 2005;72(5):833–838. - PubMed
-
- Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clin Dermatol. 2011;29(2):173–179. - PubMed
-
- Beurey J, Weber M, Percebois G. Etude clinique et mycologique des intertrigos des pieds [Clinical and mycologic study of intertrigo of the feet] Phlebologie. 1969;22(1):73–79. French. - PubMed
-
- Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol. 1991;127(2):165–166. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources